The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 21, 2010
Filed:
Dec. 06, 2005
José Maria Cid-núñez, Toledo, ES;
Antonius Andrianus Hendrikus Petrus Megens, Beerse, BE;
Andrés Avelino Trabanco-suárez, Olias del Rey, ES;
Mohamed Koukni, Leuven, BE;
Georges Joseph Cornelius Hoornaert, Kessel-Lo, BE;
Frans Josef Cornelius Compernolle, Herent, BE;
Tomasz Kozlecki, Wroclaw, PL;
Hua Mao, Fayetteville, AR (US);
Sushil Chandra Jha, Hull, GB;
Francisco Javier Fernández-gadea, Toledo, ES;
José Maria Cid-Núñez, Toledo, ES;
Antonius Andrianus Hendrikus Petrus Megens, Beerse, BE;
Andrés Avelino Trabanco-Suárez, Olias del Rey, ES;
Mohamed Koukni, Leuven, BE;
Georges Joseph Cornelius Hoornaert, Kessel-Lo, BE;
Frans Josef Cornelius Compernolle, Herent, BE;
Tomasz Kozlecki, Wroclaw, PL;
Hua Mao, Fayetteville, AR (US);
Sushil Chandra Jha, Hull, GB;
Francisco Javier Fernández-Gadea, Toledo, ES;
Janssen Pharmaceutica NV, , BE;
Abstract
This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HTand 5-HTreceptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim